Lymphoma

Non-Hodgkin's Lymphoma

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have at least on bi- 
    dimensionally measurable lesion <: 1.5 cm.
  • Must have had at least one prior anti-cancer treatment

SCRI HEMREF-34

An Open-Label, Phase lb Study of IPl-145 in
Combination with Bendamustlne, Rituximab or Bendamustine/Rituximab in Select Subjects with
Lymphoma or Chronic Lymphocytic Leukemia cancer treatment.

 

 

 

 

 

  

Criteria to qualify for study: Drug used in study:
  • Bidimensionally measurable disease of at least 1.5 cm
  • Patients who have been treated with
    single agent rituximab or corticosteroids
    as monotherapy are excluded.
  • No ALCL
  • PLT must be >50, ANC must be >1000
  • Patient does not have to be CDE30 positive

SGN35-012 

A Phase 2 study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma (NHL)

(DLBC Only)

 

 

 

 

 

  

 

Refractory/ Aggressive

Criteria to qualify for study: Drug used in study:
  • Must have stable disease or progressive disease as best response to most recent chemo or progresion within 12 months of prior auto transplant
  • Must have at least 1 measurable lesion
  • Must have MRI of the brain showing no evidence of CNS
  • No prior thereapy with a CD-19 target therapy

KTE-C19-101 Kite Pharma

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

 

 

 

 

 

 

 

Refractory/Indolent

Criteria to qualify for study: Drug used in study:
  • Follicular, marginal zone, SLL allowed.  Mantle cell, DLBC excluded
  • Induction regimen must have contained at least one alkylating agent or purine nucleoside antagonist.

LYM 87  SCRI  Infinity

A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma

 

 

 

 

 

Relapsed/Refractory

Criteria to qualify for study: Drug used in study:
  • —Must have previously received at least 2 prior systemic regimens with a CD20 target therapy, an alkylatnig agent, an anthracycline, or a steroid
  • Cannot be eligible for transplant 
  • Cannot have primary mediastinal (thymic) large B-cell lymphoma or CNS involvement 
  • Cannot have prolonged QTc interval

LYM 101 SCRI   

A Phase II Study of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.  WOLVERINE.   

 

 

 

 

 

 

Relapsed Refractory for Phase II  Untreated for Phase IB

Criteria to qualify for study: Drug used in study:
  •  Phase IB - Patients must have histologically confirmed B-cell NHL (and have never received R-CHOP treatment), except MCL or SLL
  • Any relapsed/refractory patients who are enrolled during the dose excalation should have received only a single previous treatment regimen.
  • Phase II - Patients must have previously untreated DLBCL
  • IPI Score must be 2-5

LYM 101 SCRI   

A Phase IB/II, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination with Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL     

COMING SOON  

 

 

 

 

 

 

 

 

 

 

 

 

 

Hodgkin's Lymphoma

Criteria to qualify for study: Drug used in study:
  • ŸBi-dimensionally measurable disease of 
    at least 1.5 cm 
  • Patients cannot have received more than 1 prior chemotherapy regimen for HL
  • Must be in 1st relapse

SGN35-016

A Phase 1/2 Single-Arm, Open-Label Study to Evaluate The Safety and Efficacy of Brentuximab Vedotin in combination with  Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • —Hemoblobin A1C must be ≤ 6.4% 
  • Patient must  be tested for and be negative for HIV, Hep B & C 
  • PLT must be at least 75
  • ANC must be at least 1000
  • Creatinine ≤ 1.5 x ULN or Cr Cl ≥ 50 ml/min

SCRI  LYM 90

 A Phase 1 Study of CPI-0610, a Small Melecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma

 

 

 

 

 

 


Relapsed/Refractory

Criteria to qualify for study: Drug used in study:
  • —Must have previously received at least 2 prior systemic regimens with a CD20 target therapy, an alkylatnig agent, an anthracycline, or a steroid
  • Cannot be eligible for transplant 
  • Cannot have primary mediastinal (thymic) large B-cell lymphoma or CNS involvement 
  • Cannot have prolonged QTc interval

LYM 101 SCRI   

A Phase II Study of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.  WOLVERINE.